论文部分内容阅读
目的探讨孟鲁司特联合沙美特罗替卡松粉吸入剂治疗重度哮喘患者的临床疗效。方法选取2014年2月至2015年2月河源市人民医院收治的85例重度哮喘患者作为研究对象,采用随机数字表法将患者分为单药组(43例)和联合组(42例)。单药组患者给予沙美特罗替卡松粉吸入剂,联合组患者在对照组基础上采用孟鲁司特进行治疗,比较两组患者临床效果。结果联合组相比于单药组重度哮喘控制率更高,差异有统计学意义(P<0.05);治疗后,联合组患者的用力呼气量(FEV)、第1秒钟用力呼气容积(FEV1)、最大呼气流量(PEF)、日间症状评分、夜间症状评分明显优于单药组,差异均有统计学意义(均P<0.05);联合组患者咳嗽、气喘、肺部症状消失时间及住院时间均明显短于单药组,差异均有统计学意义(均P<0.05)。结论孟鲁司特联合沙美特罗替卡松粉吸入剂治疗重度哮喘临床疗效确切,可有效改善患者症状,提高肺功能,促使其早日恢复。
Objective To investigate the clinical efficacy of montelukast combined with salmeterol and fluticasone in inhalation in patients with severe asthma. Methods Eighty-five patients with severe asthma admitted from February 2014 to February 2015 in Heyuan Municipal People’s Hospital were enrolled. Patients were divided into single drug group (n = 43) and combination group (n = 42) by random number table. Patients in the monotherapy group received salmeterol and fluticasone inhalation. Patients in the combination group were treated with montelukast on the basis of the control group, and the clinical effects were compared between the two groups. Results Compared with single drug group, the control rate of severe asthma was higher in the combined group (P <0.05). After treatment, forced expiratory volume (FEV), forced expiratory volume in 1 second (FEV1), maximum expiratory flow (PEF), daytime symptom score and nighttime symptom score were significantly better than those in the single drug group (all P <0.05); cough, asthma, lung symptoms Disappear time and hospitalization time were significantly shorter than single drug group, the difference was statistically significant (P <0.05). Conclusion Montelukast combined with salmeterol and fluticasone powder inhalation for the treatment of severe asthma clinical curative effect is exact, can effectively improve the symptoms of patients, improve lung function and promote its early recovery.